Back to Search
MICHAEL AMES, MD
MD
Hospitalist Physician
NPI: 1255622643IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hospitalist PhysicianPrimary
Hospitalist
Code: 208M00000X
MD61128742(WA)
Education
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO SCHOOL OF MEDICINE
Class of 2011
Research & Publications (20)
Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.
PMID 19648970·Bone Marrow Transplant·2010
3-trial
Endocrine therapy in 2009: consideration of the tumor and the host.
PMID 19323295·Oncology (Williston Park)·2009
8-other
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
PMID 19066728·J Neurooncol·2009
3-trial
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
PMID 19307505·J Clin Oncol·2009
3-trial
Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
PMID 17882159·Clin Pharmacol Ther·2008
6-review
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin.
PMID 17909811·Cancer Chemother Pharmacol·2008
3-trial
Response to ropinirole in restless legs syndrome is independent of baseline serum ferritin.
PMID 18645218·J Neurol Neurosurg Psychiatry·2008
8-other
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.
PMID 18757419·Cancer Res·2008
8-other
Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study.
PMID 18715950·Neuro Oncol·2008
3-trial
Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
PMID 18556440·Drug Metab Dispos·2008
8-other
Comparative bioavailability of sulindac in capsule and tablet formulations.
PMID 18349286·Cancer Epidemiol Biomarkers Prev·2008
4-observational
Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine.
PMID 18606965·Neurology·2008
2-rct
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
PMID 18794098·Clin Cancer Res·2008
8-other
Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption.
PMID 17868966·Food Chem Toxicol·2008
7-preclinical
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
PMID 18339879·Cancer Res·2008
8-other
Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy.
PMID 18413808·Mol Cancer Ther·2008
8-other
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.
PMID 18509065·Mol Pharmacol·2008
8-other
A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study.
PMID 17668866·Pediatr Blood Cancer·2008
3-trial
Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates.
PMID 16855840·Cancer Chemother Pharmacol·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1035 116TH AVE NE
BELLEVUE, WA 98004 - Phone
- (425) 403-7948
Quick Facts
- NPI
- 1255622643
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 15
- Publications
- 20
Are you this provider?
Claim Your Profile